68Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost
The purpose of our study was to show the feasibility and potential benefits of using 68Ga-PSMA-PET/CT imaging for radiation therapy treatment planning of patients with primary prostate cancer using either integrated boost on the PET-positive volume or localized treatment of the PET-positive volume. The potential gain of such an approach, the improvement of tumor control, and reduction of the dose to organs-at-risk at the same time was analyzed using the QUANTEC biological model.
Twenty-one prostate cancer patients (70 years average) without previous local therapy received 68Ga-PSMA-PET/CT imaging. Organs-at-risk and standard prostate target volumes were manually defined on the obtained datasets. A PET active volume (PTV_PET) was segmented with a 40% of the maximum activity uptake in the lesion as threshold followed by manual adaption. Five different treatment plan variations were calculated for each patient. Analysis of derived treatment plans was done according to QUANTEC with in-house developed software. Tumor control probability (TCP) and normal tissue complication probability (NTCP) was calculated for all plan variations.
Comparing the conventional plans to the plans with integrated boost and plans just treating the PET-positive tumor volume, we found that TCP increased to (95.2 ± 0.5%) for an integrated boost with 75.6 Gy, (98.1 ± 0.3%) for an integrated boost with 80 Gy, (94.7 ± 0.8%) for treatment of PET-positive volume with 75 Gy, and to (99.4 ± 0.1%) for treating PET-positive volume with 95 Gy (all p < 0.0001). For the integrated boost with 80 Gy, a significant increase of the median NTCP of the rectum was found, for all other plans no statistical significant increase in the NTCP neither of the rectum nor the bladder was found.
Our study demonstrates that the use of 68Ga-PSMA-PET/CT image information allows for more individualized prostate treatment planning. TCP values of identified active tumor volumes were increased, while rectum and bladder NTCP values either remained the same or were even lower. However, further studies need to clarify the clinical benefit for the patients applying these techniques.
KeywordsPSMA Prostate cancer Radiation treatment planning PET/CT
This project was funded in part by the Deutsche Forschungsgemeinschaft (BU 3395/1–1).
Compliance with ethical standards
Conflict of interest
RB has a research contract with Mediso GmbH Germany. Mediso GmbH Germany provided the Mediso Interview Fusion Tool for image analysis within this project. RB and ME are members of the advisory board of Bayer Healthcare, Leverkusen, Germany. All other authors declare that they have no conflicts of interest.
Due to the retrospective character of the study, ethical approval was waived by the institutional ethics committee.
All patients gave written informed consent about the performed procedures and the fact that all data may be used for retrospective scientific analyses.
- 5.van Lin EN, Futterer JJ, Heijmink SW, van der Vight LP, Hoffmann AL, van Kollenburg P, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65:291–303.CrossRefPubMedGoogle Scholar
- 6.Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol (London, England). 2012;7:14.CrossRefGoogle Scholar
- 13.Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic Efficacy of Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging in Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2015.Google Scholar
- 15.Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, et al. INtegration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol (London, England). 2016;11:73. https://doi.org/10.1186/s13014-016-0646-2.
- 16.Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, et al. Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1400–6. https://doi.org/10.1007/s00259-016-3346-0.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Zamboglou C, Wieser G, Hennies S, Rempel I, Kirste S, Soschynski M, et al. MRI versus (6)(8)Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:889–97. https://doi.org/10.1007/s00259-015-3257-5.CrossRefPubMedGoogle Scholar
- 19.Zamboglou C, Schiller F, Fechter T, Drendel V, Mix M, Meyer PT, et al. A voxel-wise comparison of (68)ga-Hbed-CC-PSMA PET/CT versus histopathology in primary localized prostate cancer: implementations for radiation therapy treatment planning. Int J Radiat Oncol. 2016;96:E253–E4.CrossRefGoogle Scholar